The public markets welcomed another biotech company this past week with the $81 million stock market debut of Vogenx, a metabolic medicines developer whose in-licensed lead drug candidate is in clinical testing for a disorder that currently has no FDA-approved therapies.
Vogenx priced 6.25 million shares at $13 each, which was the top end of its targeted price range. Those shares began trading on the Nasdaq on Aug. 12 under the stock symbol “VOGX.” Raleigh, North Carolina-based Vogenx finished its first week as a public company trading at $14.78 per share, up 13% from the IPO price.
The lead disease target of Vogenx is post-bariatric hypoglycemia (PBH), a steep drop in blood sugar that happens after eating. PBH develops as the changed anatomy of the gut from bariatric surgery leads the intestines to rapidly absorb glucose. The resulting dangerously low blood sugar levels can cause patients to experience cognitive problems, dizziness, weakness, vision loss, loss of consciousness, and seizures. PBH is a late complication of bariatric surgery that can start six months to several years following the procedure.
Vogenx’s mizagliflozin is an oral small molecule designed to inhibit SGLT1, a transporter protein responsible for glucose absorption. There are several FDA-approved SGLT2 inhibitors for type 2 diabetes and heart failure. Lexicon Pharmaceuticals’ heart failure drug Inpefa, a dual inhibitor of SGLT1 and SGLT2, is the only approved molecule that addresses SGLT1. Vogenx believes its molecule can stand apart from its competitors in PBH.
“Compared to alternative treatments in development, we believe the unique mechanism of action of mizagliflozin may provide better efficacy with respect to reducing hypoglycemic events, potentially have fewer side effects, and may allow patients to have fewer dietary restrictions and an improved quality of life,” the company said in the IPO filing.
Elevated SGLT1 increases the quantity and rate of glucose absorption, which in turn leads to increased secretion of the hormones GIP and insulin, Vogenx said in the filing. Mizagliflozin is a selective inhibitor of SGLT1 that works specifically in the intestinal lumen, a part of the small intestine that absorbs nutrients from food. Vogenx said gastric bypass patients have shown overexpression of SGLT1 in the intestinal lumen.
So far, Vogenx has completed two Phase 2 tests of mizagliflozin in PBH. The company reported statistically significant reduction in glucose absorption and insulin secretion after a meal. Results also showed reduction in hypoglycemic events compared to a placebo. The company is now preparing for a Phase 2b test of mizagliflozin in PBH.
Mizagliflozin may have applications in other metabolic indications. The company also plans to conduct a Phase 2 proof-of-concept trial of the drug in gastroparesis, a digestive disorder in which the stomach muscles don’t move food, leading to a delay in gastric emptying. Vogenx also plans to submit an investigational new drug application to test the drug in patients diagnosed with GIP-dependent Cushing’s syndrome (GDCS), a rare disease in which excess cortisol leads to problems such as excessive weight gain.
Of the companies developing PBH drugs, Vogenx is the only one with a drug candidate offering oral dosing, albeit one that’s taken three times daily. Amylyx Pharmaceuticals has the most advanced PBH program with avexitide, a once-daily injectable GLP-1 antagonist that the biotech acquired last year. In its report of second quarter 2026 financial results, Amylyx said it expects preliminary Phase 3 results will read out in late August or early September.
Recordati is developing pasireotide , an insulin secretion-blocking peptide injected before each meal. Earlier this year, the rare disease drug developer reported Phase 2 results showing an increase in blood glucose following a meal. The company expects to complete a Phase 3 development plan for pasireotide in PBH by the end of this year.
MBX Biosciences had the opportunity to offer PBH patients the longest dosing interval with imapexitide (formerly MBX 1416). This long-acting GLP-1 antagonist was intended to be a once-weekly injection. While Phase 2 results reported in May showed proof of concept, the company said it would not invest in a Phase 2b trial. Instead, MBX’s priorities are now Phase 3 development of its most advanced program, canvuparatide, for chronic hypoparathyroidism, as well as its obesity drug candidates.
Vogenx was founded in 2021. The following year, the company licensed mizagliflozin from Japan-based Kissei Pharmaceuticals. The deal gave Vogenx global rights to mizagliflozin except for Japan, Korea, and Taiwan. According to the IPO filing, Vogenx paid $1 million up front and could pay out up to $27 million more tied to milestones; Kissei is also eligible to receive royalties from sales of an approved drug.
In its history as a private company, Vogenx said it had raised $11.5 million in funding, a Series A round that closed in 2022. As of the end of the first quarter of 2026, Vogenx reported its cash position was $251,000, which the company said would not last for the next 12 months. With the IPO proceeds, the biotech plans to spend $26.3 million to advance mizagliflozin through Phase 2b testing in PBH; preliminary results are expected in 2027. Another $20.4 million will support Phase 2 testing of the molecule in gastroparesis. Vogenx estimates its capital will support the company through 2028.
Photo: Getty Images
